SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cytokine1 who wrote (1967)8/12/1997 9:44:00 PM
From: scaram(o)uche  Read Replies (1) of 9719
 
I see that CLTR is in the portfolio. IDPH hasn't made much noise lately about the concept that anti-CD20 inhibits the expression of bcl-2 and therefore might enhance the efficacy of CHOP.

I like CLTR, and appreciate the dilligent efforts that have led this far. This question is asked from ignorance. It is not an attempt to shoot CLTR down. But..... if anti-CD20 and CHOP are significantly more effective than CHOP alone, doesn't that spell big trouble for CLTR? I presume that Coulter's PLA will be reviewed well before any final conclusions can be drawn from the CHOP studies, so maybe this isn't a near-term concern?

Also..... IDPH and GNE announced 2/20/96 that they planned to take an anti-CD20 yttrium conjugate into phase II during '96. Did they? Any news?

Thanks for any help.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News